Listen to this page using ReadSpeaker

ACT’s Stem Cell Clinical Trial Expanding to Bascom Palmer

Woman looking through microscopeI am pleased to report that Advanced Cell Technology (ACT) just received institutional review board approval to add Bascom Palmer Eye Institute in Miami, Florida, as a clinical trial site for its stem-cell-derived treatment for people with dry age-related macular degeneration (AMD). Bascom Palmer has been ranked by U.S. News & World Report as the best ophthalmology hospital in the U.S. for the last eight years, so they are no doubt a valuable addition to the study.

ACT’s clinical trial of its treatment for dry AMD is also taking place at UCLA and Wills Eye Institute in Philadelphia.

The clinical trial of the same treatment for Stargardt disease is underway at UCLA and Wills, as well as Grampian University Hospitals and Moorfields Eye Hospital in the U.K.

Earlier this year, ACT announced encouraging results for the first two trial participants treated, one with dry AMD and the other with Stargardt disease. There were no adverse events, and the cells provided modest vision improvement.

The expansion of these studies to additional sites and the treatment of more participants will provide more information about the treatment’s potential for saving vision. I look forward to reporting additional clinical trial results as they are made available.

If you haven’t done so already, make sure you read Dr. David Gamm’s guest blog post on his outstanding stem cell research and the enormous potential it has as both a treatment and a research tool.

9 Responses to 'ACT’s Stem Cell Clinical Trial Expanding to Bascom Palmer'

  1. MARK MAURER says:

    Could this clinical trail also help my wife who is blind due to an atrophied retina in her right eye and optical nerve damage in her left eye. If clinical trails are being conducted could her name be added to the list asap? Please advise


  2. Maria Dorst says:

    Which criteria has to be met in order to be admitted to this trial. My father has dry AMD, however he does not live in the U.S.



  3. My mother has dry AMD and I was wanting to know how she could get on the list for the trial study at Bascom Palmer Eye Institute. I look forward to hearing from you. Thank you

    • EyeOnTheCure says:

      Hi Debbie, thanks for commenting

      Here is a link to the clinical trial listing as well as contact information at Bascom-Palmer:

    • Jean Marie Estadt says:

      I am a very active seventy-six year old diagnosed with dry Macular Degeneration in July of 2012. I would be interested in being part of any current dry
      Macular Degeneration Trials,

      • EyeOnTheCure says:

        Dry AMD is most common type of macular degeneration and accounts for more than 90% of all AMD. In the dry form, the retinal pigment epithelial cells (RPE) sicken and die in the macula. These RPE cells support the light sensitive photoreceptor cells that are so critical to vision. Dry AMD is often referred to as atrophic AMD and is characterized by the presence of drusen within the macula. To read more about AMD please see the following web link:
        The government website: http://WWW.CLINICALTRIALS.GOV lists all of the “legitimate” clinical trials taking place. If you query in “DRY AMD”, you will see approximately 30 trials that are recruiting patients for clinical trials. Here is the web link:
        You will need to look at each trial to see whether or not you fit the inclusion and exclusion criteria. Some trials pay for travel and some do not and each trial should list a phone number where you can call for more information.

  4. john graybeal says:

    Would love to receive your news letter regarding Macular degeneration dry

Leave a Reply

Your email address will not be published. Required fields are marked *